Business context and reporting period
Grifols, S.A. filed an audited IFRS annual report for the fiscal year ended December 31, 2018. This is a full-year 20-F, not a standalone fourth-quarter report; the supplied filing text does not provide separate Q4 financial results. Grifols is a global plasma-derived medicines and diagnostics company, with Bioscience accounting for 78.4% of 2018 revenue.
Financial performance and liquidity
Amounts below are in euros; financial statement figures are in millions unless noted. Revenue growth at constant currency is a non-IFRS measure.
| Metric | 2018 | 2017 | Change |
|---|---|---|---|
| Revenue | €4,486.7m | €4,318.1m | +3.9%; +9.2% at constant currency |
| Gross profit / margin | €2,049.6m / 45.7% | €2,152.0m / 49.8% | Profit down 4.8%; margin down 4.1 percentage points |
| Operating result / margin | €994.1m / 22.2% | €1,003.3m / 23.2% | Down 0.9% |
| Profit attributable to parent | €596.6m | €662.7m | Down 10.0% |
| Basic EPS | €0.87 | €0.97 | Down 10.3% |
| Operating cash flow | €737.4m | €841.7m | Down 12.4% |
| Capital expenditure additions | €316.7m | €340.5m | Down 7.0% |
Cost of sales rose 12.5% to €2,437.2m, reaching 54.3% of revenue versus 50.2% in 2017. Management attributed the margin pressure primarily to higher plasma procurement costs; it also cited China albumin sales restrictions, Factor VIII sales mix, tender volatility and diagnostic product mix. R&D expense was €240.7m, down from €288.3m; the 2017 figure included a specific Aradigm impairment, while 2017 recurring R&D excluding that impairment was €223.7m.
At year-end, cash and cash equivalents were €1,033.8m, inventories €1,949.4m, current assets €3,483.3m and current liabilities €1,257.3m. Current and non-current financial liabilities totaled approximately €6,376.8m; subtracting reported cash gives simple net debt of approximately €5,343.0m, not a company-reported covenant measure. Cash flow was €781.9m negative from investing and €152.5m positive from financing; cash increased €147.3m during the year. Interest paid was €225.1m.
Material changes versus the prior year
- Revenue increased, led by Bioscience growth of 8.0% at constant currency. Immunoglobulin, albumin and alpha-1 antitrypsin sales grew, while Factor VIII sales declined.
- Gross margin contracted as plasma costs rose; operating result was broadly flat and parent-attributable profit fell.
- Operating cash flow declined, in part as inventories increased by €231.7m to support expected plasma-protein demand. Inventory turnover rose to 292 days from 275 days.
- Finance costs increased 11.3% to €293.3m. Reported 2017 tax expense was unusually low, reflecting a €171.6m positive non-recurring effect from U.S. tax reform; 2018’s effective tax rate was 18.1%.
- Cash flow from investing was substantially less negative than in 2017, when the Hologic acquisition drove investment outflows. In 2018, the Group acquired MedKeeper, Haema and Biotest US, then sold Haema and Biotest US to a related party.
Outlook, commentary, risks and unusual items
- Management expected operating cash flow, cash balances and available credit to cover obligations, working capital and capital expenditures for at least 12 months. However, the filing gives conflicting figures for year-end cash and available credit; see investor verification items.
- Plans include a 20% subcutaneous immunoglobulin launch in the second half of 2019, approximately 19 million liters of fractionation capacity by 2021, and 325 approved plasma centers globally by 2023. The filing describes a €1.2bn 2016–2020 investment plan and approximately €400m of Bioscience industrial capital investment during 2019–2020. These are plans, not guaranteed outcomes.
- Management cited expected long-term global plasma-derived product market growth of 6%–7%; this is an industry outlook, not specific company revenue guidance.
- The completed Haema and Biotest US acquisitions cost approximately $506m in aggregate and the businesses were sold in December 2018 to Scranton, a related party, for $538m. Grifols retained operating arrangements, a 30-year plasma supply agreement and an option to repurchase the shares. Scranton received a $95m-equivalent loan from a Grifols subsidiary at EURIBOR plus 200 basis points. The Group continued consolidating the businesses, treating the sale as an equity transaction without profit-and-loss impact.
- The Phase III AMBAR Alzheimer’s study reported a statistically significant 61% reduction in disease progression on the reported primary endpoints in moderate-disease patients. This is a study result, not an approved treatment indication.
- Key risks include high leverage, variable-rate debt, foreign exchange exposure, plasma supply and collection capacity, manufacturing quality and regulatory compliance, product liability, pricing and reimbursement pressure, and competition. Approximately 81.2% of senior interest-bearing debt was variable-rate; management estimated a 100-basis-point rate rise would increase 2018 interest expense by €53m. A 10% stronger U.S. dollar was estimated to increase equity by €506.1m.
- Legal proceedings included patent litigation concerning Procleix products. Management said it did not expect the identified proceedings to have a material financial impact; the Enzo case ended in judgment for Grifols and Hologic in November 2018, subject to Enzo’s stated intention to appeal.
- The auditor issued unqualified opinions on the consolidated financial statements and internal control over financial reporting. Management also concluded disclosure controls and internal control were effective at year-end.
Most important facts an investor should verify
- Reconcile year-end cash: the audited balance sheet and cash flow statement report €1,033.8m, while the liquidity discussion states €886.5m.
- Reconcile available credit: the liquidity discussion cites approximately €380m, while the detailed risk note reports €404.8m of unused facilities, including €262.0m on the revolving facility.
- Review the related-party Haema/Biotest sale, financing, continued consolidation, plasma supply terms and repurchase option, including the applicable approvals and disclosures.
- Assess the sustainability of margins and cash generation given higher plasma costs, rising inventory and substantial debt service.
- Track execution, regulatory approvals and funding for capacity projects and planned launches; distinguish management plans and industry forecasts from formal company guidance.
- Monitor AMBAR follow-up evidence and regulatory status before assigning commercial value to the Alzheimer’s findings.